Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX2TZD)

Drug Name

DR-5/DR-4 cross reactive mabs Drug Info

Synonyms

DR-5/DR-4 cross reactive mAbs (cancer); Death receptor-5/4 cross reactive mAbs (cancer), Crystal Bioscience; DR-5/DR-4 cross reactive mAbs (cancer), Crystal Bioscience

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Investigative	[1]

Cross-matching ID

TTD Drug ID: DMX2TZD

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting TRAIL receptor 2 (TRAIL-R2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[3]
Lexatumumab	DMOS5JZ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
Anti-DR5 cells	DMYKZB3	Hepatocellular carcinoma	2C12.02	Phase 1/2	[5]
IGM-8444	DMFJXDZ	Hematologic tumour	2B33.Y	Phase 1	[6]
INBRX-109	DMUNSPI	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
BI 905711	DME9NYV	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
DS-8273	DMJPUDW	Colorectal cancer	2B91.Z	Phase 1	[9]
GEN1029	DMV8IWJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
RhApo2L/TRAIL	DMIAZJ9	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1/2	[3]
LBY-135	DMSRD5U	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting TRAIL receptor 1 (TRAIL-R1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mapatumumab	DMGQ175	Non-small-cell lung cancer	2C25.Y	Phase 2	[12]
RhApo2L/TRAIL	DMIAZJ9	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1/2	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
TRAIL receptor 1 (TRAIL-R1)	TT5WLRX	TR10A_HUMAN	Not Available	[1]
TRAIL receptor 2 (TRAIL-R2)	TTW20TU	TR10B_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1879).
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1880).
3	Clinical pipeline report, company report or official report of Amgen (2009).
4	National Cancer Institute Drug Dictionary (drug id 528015).
5	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
6	Clinical pipeline report, company report or official report of IGM Biosciences.
7	Clinical pipeline report, company report or official report of Inhibrx.
8	Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist. Mol Cancer Ther. 2021 Jan;20(1):96-108.
9	First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35(3):298-306.
10	National Cancer Institute Drug Dictionary (drug name Tilogotamab).
11	Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Invest New Drugs. 2014 Feb;32(1):135-44.
12	National Cancer Institute Drug Dictionary (drug id 486626).